Effect of losartan therapy on endothelial function in hypertensive patients

American Journal of Therapeutics

Volumn 14, Issue 2, 2007, Pages 166-171

  Sosa Canache, Beatriz ^a   Hernández Hernández, Rafael ^a,d   Armas Padilla, María Cristina ^a   Armas Hernández, María José ^a   Cammarata Segura, Rosalba ^a   Pacheco, Beatriz ^a   Guerrero, Jaime ^a   Israili, Zafar H ^b   Valasco, Manuel ^c  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^d Unidad de Terapia Medica   (Venezuela)

Author keywords

Angiotensin at1 receptor blocker; Endothelial function; Hypertension; Losartan; Malondialdehyde; Nitric oxide; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; MALONALDEHYDE; NITRIC OXIDE;

ADULT; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ENDOTHELIUM; ESSENTIAL HYPERTENSION; FEMALE; HEART SOUND; HUMAN; HYPERTENSION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE;

EID: 34247174363     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pap.0000249919.44604.e1     Document Type: Conference Paper

References (40)

1. Gardiner SM, Compton AM, Bennett T, et al. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension. 1990;15:486-492.
2. Garg UC, Hassid A. Nitric oxide-generating vasolators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun. 1990;171:474-479.
3. López-Ongil S, Hernández-Perera O, Navarro-Antolin J, et al. Role of reactive oxygen species in the signaling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cell. Br J Pharmacol. 1998;124:447-454.
4. Maxwell AJ. Mechanisms of dysfunction of nitric oxide pathway in vascular diseases. Nitric Oxide. 2002;6:101-124.
5. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilatador. Hypertension. 1998;12:365-372.
6. Papapetropoulos A, Garcia-Cardena G, Madri JA, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100:3131-3139.
7. Rajagopalam S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations in vasomotor tone. J Clin Invest. 1996;97:1916-1923.
8. Wong PC, Price WA Jr, Chiu AT, et al. Non-peptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753. Hypertension. 1990;15:823-834.
9. Bunkenburg B, Schnell CH, Baum HP, et al. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences. Hypertension. 1991;18:278-288.
10. Seyedi N, Xu X, Nasjletti A, et al. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
11. 2 production in conscious rats. J Clin Invest. 1996;97:1978-1982.
12. 2 receptors mediate vasodepressor response to footshock in rats. Role of kinins, nitric oxide and prostaglandins. Eur J Pharmacol. 2000;394:103-108.
13. Cachofeiro V, Maeso R, Rodrigo E, et al. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension. 1995;26:236-243.
14. Naito C, Kawamura M, Yamamoto Y. Lipid peroxides as the initiating factor of atherosclerosis. Ann N Y Acad Sci. 1993;676:27-45.
15. Wong PC, Hart SS, Zaspel AM, et al. Functional studies of non-peptide angiotensin II receptor subtype-specific ligands: Dup 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther. 1990;255:584-592.
16. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997;54:299-311.
17. Hernandez-Hernandez R, Sosa-Canache B, Velasco M, et al. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens. 2002;16(Suppl 1):S93-S99.
18. Huang PL, Huang H, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
19. Ohashi Y, Kawashima S, Hirata K, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998;102:2061-2071.
20. Moncada S, Palmer RM, Higgs E A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
21. Panza J A. Endothelial dysfunction in essential hypertension. Clin Cardiol. 1997;20(Suppl 2):II-26-II-33.
22. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1998;86:3375-3378.
23. Rudic RD, Shesely EG, Maeda N, et al. Direct evidence for the importance of endothelium derived nitric oxide in vascular remodeling. J Clin Invest. 1998;101:731-736.
24. Verma S, Anderson TJ. Fundamentals of endothelium function for the clinical cardiologist. Circulation. 2002;105:546-549.
25. Takase H, Sugiyama M, Nakazawa A, et al. Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension. Arzneimittelforschung. 2000;50:530-534.
26. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. An overview. Circ Res. 2002;90:21-28.
27. Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol. 1997;12:259-264.
28. Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz. 1997;22:158-172.
29. Zalba G, San Jose G, Moreno MU, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension. 2001;38:1395-1399.
30. Berry C, Brosnan MJ, Fennell J, et al. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens. 2001;10:247-255.
31. Smith JB, Ingerman CM, Silver MJ. Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med. 1976;88:167-172.
32. Armas-Padilla MC, Armas-Hernández MJ, Hernández. Hernández R, et al. Comparative assessment of lacidipine and nifedipine GITS: effects on blood pressure, platelet function, and insulin sensitivity in patients with hypertension. Curr Therap Res Clin Exp. 2000;61:83-96.
33. Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension. 1999;34:987-996.
34. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol. 1999;128:523-529.
35. De Las Heras N, Aragoncillo P, Maeso R, et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension. 1999;34:969-975.
36. Li H, Wallerath T, Münzel T, et al. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide. 2002;7:149-164.
37. Drexler H. Hypertension, heart failure, and endothelial function. Am J Cardiol. 1998;82:20S-22S.
38. Schiffrin EL. Vascular protection with newer antihypertensive agents. J Hypertens Suppl. 1998;61:S25-S29.
39. Linz W, Heitsch H, Scholkens BA, et al. Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension. 2000;35:908-913.
40. Goetz RM, Holtz J. Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aorta from hypertensive rats: evidence for a casual link. Clin Sci (Colch). 1999;97:165-174.